{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT03418779: Phase 2/Phase 3 Interventional Active, not recruiting IgA Nephropathy at High Risk of Developing ESRD
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01721018: Phase 1/Phase 2 Interventional Completed Malignant Pleural Mesothelioma
(2012)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00066989: Phase 2 Interventional Completed Staphylococcal Infections
(2003)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
USAN:TONOGENCHONCEL-L [USAN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03410342: Not Applicable Interventional Completed Blood Pressure
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00678119: Phase 2 Interventional Completed Renal Cell Carcinoma
(2008)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02010203: Phase 1/Phase 2 Interventional Terminated Bladder Cancer
(2013)
Source URL:
Class:
STRUCTURALLY DIVERSE
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01602562: Phase 3 Interventional Completed Herpes Simplex
(2012)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00633009: Phase 2 Interventional Completed Cutaneous Leishmaniasis
(2008)
Source URL:
Class:
STRUCTURALLY DIVERSE